Skip to content

EPS (Basic) at other companies

Celcuity logo
CelcuityCELC
-$0.97-12.8%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$2.29-103%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$0.67+69.7%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$1.02+10.5%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$1.11-35.4%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$0.53-1.9%

Other financials

Income statement

See full
Revenue$3.0M-60.9%
Operating income-$78.6M+7.4%
Net income-$73.3M+4.9%
EPS (diluted)-$0.41+10.9%

Balance sheet

See full
Cash & equivalents$204.6M+119%
Total debt$31.6M-33.1%
Total equity$642.2M-10.9%
Total assets$699.6M-12.5%

Cash flow

See full
Operating cash flow-$51.1M+30.2%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$3.8B+300%

Profitability

See full
Operating margin-2,776.6%-820pp
Net margin-2,554.1%-745pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-40%-4.3pp
Debt / equity0.0×
Current ratio22.1×+2.2×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relay Therapeutics, Inc.'s eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relay Therapeutics, Inc.'s EPS (basic)?
Relay Therapeutics, Inc. (RLAY) reported EPS (basic) of -$0.41 in Q1 2026.
How has Relay Therapeutics, Inc.'s EPS (basic) changed year-over-year?
Relay Therapeutics, Inc.'s EPS (basic) increased by 10.9% year-over-year, from -$0.46 to -$0.41.
What is the long-term trend for Relay Therapeutics, Inc.'s EPS (basic)?
Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s EPS (basic) has grown at a -19.4% compound annual growth rate (CAGR), from -$3.82 to -$1.61.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.